Exagen (XGN)
(Delayed Data from NSDQ)
$1.39 USD
+0.03 (1.84%)
Updated May 2, 2024 03:53 PM ET
After-Market: $1.38 -0.01 (-0.36%) 4:54 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Brokerage Reports
Exagen Inc. [XGN]
Reports for Purchase
Showing records 1 - 20 ( 36 total )
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
3Q23 ASP Strategy Coming to Fruition and Partnerships Aiding LT Visibility
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
2Q23 Appeals Process Gaining Momentum and Improved ASPs
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
1Q23 - Beats Expectations - New CEO Displays Decipher Background
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
2023 KBCM Life Sciences & MedTech Forum: Day 2 Takeaways
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
4Q22 - AVISE Price/Volume Results in 2023 to Drive LT Visibility
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Coverage vs. Pricing of Lupus Test; Medicare Primer
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Reimbursement Gone Wrong - Downgrading to SW
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department